Key Highlights
-
Perimenopause and menopause can lead to a significant increase in visceral fat and loss of muscle.
-
Body composition is more indicative of overall health than weight itself.
-
GLP-1 agonists like Ozempic may accelerate muscle loss, potentially increasing menopausal frailty risk.
-
HRT presents an alternative weight management tool that improves bodily composition including fat redistribution.
-
HRT also helps preserve muscle and bone health, unlike GLP-1 agonists, which may exacerbate frailty.
Introduction
How Does Menopause Influence Body Composition
The hallmark of menopause is when you experience your final menstrual period. However, perimenopause can start up to 10 years before menopause; many women start hormone therapy during perimenopause.
The Connection Between Menopause And Weight Gain
Estrogen helps modulate the body’s fat distribution, supports muscle maintenance, and influences energy expenditure.
The Connection Between Menopause And Frailty
“Muscle is the organ of longevity.” Dr. Gabrielle Lyon
During menopause, many women experience a significant increase in frailty due to interconnected physiological changes. This includes:
-
Loss of muscle mass. Reduced estrogen levels accelerate muscle loss. Research finds that women in late perimenopause had 10% less muscle mass than women in early perimenopause. [4]
-
Loss of bone density. The decline in estrogen adversely affects bone density; women lose up to 20% of bone mass during menopause. [5]
Frailty is not just a physical condition; it is closely linked to overall health. Research indicates that frailty is a strong predictor of lifespan and healthspan. [6]
What is Ozempic or Semaglutide?
Can Ozempic Be Used For Menopausal Weight Gain?
Study Demonstrating Ozempic Weight Loss Efficacy
One notable study published in the New England Journal of Medicine investigated the effects of the active ingredient semaglutide in Ozempic on a group of nearly 2,000 adults with obesity. [7]
The study participants, a majority of whom were postmenopausal women, were either given semaglutide or a placebo. The results demonstrated significant weight loss in postmenopausal women in the semaglutide group.
|
Group |
Average Weight Loss |
|
Semaglutide |
15% |
|
Placebo |
2.4% |
However, ozempic can also result in muscle loss. A recent study showed that those taking Ozempic, or any form of semaglutide, lost a ratio of 60% fat and 39% muscle mass. [7]
Does Ozempic Increase Frailty Risk In Menopausal Women?
While there is no conclusive research to establish that Ozempic can lead to frailty or musculoskeletal syndrome, individuals can lose muscle mass on this drug.
To avoid increasing risks of sarcopenia and musculoskeletal syndrome, it’s critical to actively monitor nutrition, specifically protein intake.
“Women in perimenopause should eat more, not less.” Dr. Mary Claire Haver, Certified Menopause Specialist
Even though Ozempic may reduce our appetite and caloric intake, menopausal women should prioritize nutrition and musculoskeletal health for long-term well-being.
HRT for Menopausal Weight Management
HRT Improves Body Composition in Menopausal Women
-
Weight Gain Prevention. HRT helps prevent weight gain from estrogen deficiency in the body. [8]
-
Fat Redistribution. HRT specifically targets visceral fat, the main culprit in menopausal weight gain. This can reduce several health effects associated with this symptom. [9]
-
Supports Musculoskeletal Health: Estrogen plays a key role in maintaining muscle and bone health. By restoring estrogen levels, HRT helps preserve muscle mass and bone density, reducing the risk of frailty. [10]
HRT vs Ozempic for Menopausal Weight Management
Navigating weight management during menopause involves evaluating different treatment options.
|
Feature |
HRT |
Ozempic |
|
Weight Loss |
Modest, combats weight gain |
Average loss of 15% body weight |
|
Muscle Health |
Preserves muscle mass |
May reduce muscle mass. |
|
Bone Density |
Protects against osteoporosis |
No protective effect on bone density |
|
Frailty Risk |
Reduces risk by maintaining strength |
May increase frailty risk |
|
Body Composition |
Targets abdominal fat |
Targets all body weight, not just fat |
|
Primary Use |
Alleviates menopausal symptoms and health risks |
Primarily for weight management |
HRT not only alleviates menopausal symptoms but also protects muscle and bone health, reducing the risk of frailty. [10]
Unsure What To Do?
If you are experiencing menopausal symptoms, you may be in perimenopause and should schedule a consultation with your physician. Try to see a certified menopause practitioner.
If you’re seeking support and access to evidence-based resources, explore the Timeless community.
Sign up for our waitlist to receive more data-driven women’s health tips!
Frequently Asked Questions
Can Ozempic be used as a primary treatment for menopause symptoms?
Ozempic is not specifically approved for treating menopause symptoms. While it may alleviate certain symptoms, it’s crucial to consult with your healthcare provider to determine the most effective treatment plan, which may include hormone therapy or other approaches to address estrogen decline.
How quickly can improvements be noticed after starting Ozempic?
Improvements in blood sugar levels may be noticeable sooner, while significant weight loss may take several weeks. Incorporating healthy lifestyle changes like regular physical activity and a balanced diet can enhance Ozempic’s effectiveness. Discuss your progress with your healthcare provider.
Are there any lifestyle changes recommended when taking Ozempic?
Yes, adopting healthy lifestyle changes can optimize Ozempic’s benefits. Focus on balanced nutrition, including absorbable protein, fiber and regular strength and endurance exercises
This article is for informational purposes only and not a substitute for professional medical advice. Always consult a qualified healthcare provider with any questions regarding medical conditions.
References
-
https://www.sciencedirect.com/science/article/pii/S075333220100155X?via%3Dihub
-
https://nyaspubs.onlinelibrary.wiley.com/doi/10.1111/j.1749-6632.2000.tb06506.x
-
https://journals.physiology.org/doi/full/10.1152/japplphysiol.00315.2019
-
https://academic.oup.com/jbmr/article/18/2/333/7592572#google_vignette
-
https://www.tandfonline.com/doi/abs/10.1517/14656566.1.6.1163
-
https://jamanetwork.com/journals/jamaoncology/fullarticle/2811413


